Eysuvis

Eysuvis

Generic: Loteprednol etabonate 0.25%

Eysuvis
DOSAGE 1 gtt up to QID for up to 14 days
GENERIC Loteprednol etabonate 0.25%
SIZE 8.3 mL
INDICATIONS EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
MECHANISM OF ACTION Ester based corticosteroid
MICROBIOLOGY Thought to prevent dry eye caused by ocular inflammation associated with keratoconjunctivitis sicca | Loteprednol etabonate is lipid soluble and can penetrate into cells. Loteprednol etabonate is synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. Based upon in vivo and in vitro preclinical metabolism studies, loteprednol etabonate undergoes extensive metabolism to inactive carboxylic acid metabolites, PJ-91 and PJ-90.
CONTRAINDICATIONS & WARNINGS Contraindicated in patients with viral, bacterial, or fungal eye infections
PEDIATRIC USE Safety and effectiveness in pediatric patients have not been established.
PREGNANCY Category C
NOTE